Showing 1761-1770 of 4063 results for "".
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- Aurion Biotech Announces First Subject Dosed in US Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-subject-dosed-in-us-phase-1-2-clinical-trial/2481908/Aurion Biotech announced that it has dosed the first subject in its phase 1/2 US clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “On the heels of our recent approval in Japan, we ar
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.